Home > Boards > US Listed > Biotechs > BIONDVAX PHARMACUETICALS LTD (BVXV)

BiondVax Announces Receipt of $4.2 Million Through Exercise

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
midastouch017 Member Profile
 
Followed By 110
Posts 24,084
Boards Moderated 14
Alias Born 02/07/04
160x600 placeholder
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/1/2020 8:20:36 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/1/2020 6:32:00 AM
Last of 12,400 Participants Completes Final Visit in BiondVax's M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial PR Newswire (US) - 7/1/2020 6:00:00 AM
BiondVax Announces First Quarter 2020 Financial Results PR Newswire (US) - 6/30/2020 4:01:00 PM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 6/22/2020 1:37:36 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/12/2020 8:11:32 AM
Annual and Transition Report (foreign Private Issuer) (20-f) Edgar (US Regulatory) - 6/12/2020 8:04:57 AM
BiondVax Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update PR Newswire (US) - 6/12/2020 8:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/10/2020 7:48:38 AM
NIH Report on Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Concludes Both Primary Endpoin... PR Newswire (US) - 6/10/2020 7:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/20/2020 7:44:36 AM
BiondVax Announces Receipt of $4.2 Million Through Exercise of Warrants PR Newswire (US) - 5/20/2020 6:30:00 AM
Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ... Edgar (US Regulatory) - 5/13/2020 4:34:19 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/4/2020 10:48:44 AM
BiondVax Announces Upcoming Expiration of Public Warrants PR Newswire (US) - 5/4/2020 6:30:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 4/30/2020 9:40:42 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 3/24/2020 4:28:59 PM
New Directors Elected to BiondVax's Board of Directors PR Newswire (US) - 3/24/2020 4:01:00 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 3/19/2020 1:06:02 PM
BiondVax's CEO Comments on Impact of COVID-19 Pandemic on the Company's Ongoing Phase 3 Clinical Trial PR Newswire (US) - 3/19/2020 7:15:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 2/25/2020 12:42:30 PM
Amended Report of Foreign Issuer (6-k/a) Edgar (US Regulatory) - 2/10/2020 5:22:43 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 2/10/2020 11:15:24 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 2/5/2020 3:25:39 PM
Preliminary Data from NIH/NIAID-sponsored Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Va... PR Newswire (US) - 2/5/2020 1:00:00 PM
midastouch017   Wednesday, 05/20/20 08:21:32 AM
Re: None
Post # of 377 
BiondVax Announces Receipt of $4.2 Million Through Exercise of Warrants

Wed May 20, 2020 6:30 AM|PR Newswire|About: BVXV

JERUSALEM, May 20, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV), developer of the M-001 universal influenza vaccine candidate, today announced receipt of proceeds of approximately $4.2 million since January 1, 2020 through exercises of BiondVax warrants. The publicly traded warrants, which were issued to investors in connection with BiondVax's initial public offering on Nasdaq in 2015, had an exercise price of $6.25, traded on Nasdaq under the symbol BVXVW, and expired May 15, 2020. Warrants issued to underwriters in connection with the initial public offering expired May 11, 2020.

As announced in January 2020, holders of outstanding warrants were permitted to exercise their warrants on either a cash or cashless basis. Following the warrants' exercise and expiry, there are currently 11,353,634 outstanding BiondVax American Depositary Shares ("ADSs"). BiondVax ADSs are traded on Nasdaq under the symbol BVXV.

As filed in a 6-K with the SEC on April 30, 2020, BiondVax expects to file its Annual Report on Form 20-F for the year ended December 31, 2019 no later than June 14, 2020.

BiondVax's pivotal, clinical efficacy, Phase 3 trial in Europe is ongoing. The trial, which is assessing M-001's ability to provide clinical protection from any circulating influenza strain, is being conducted with 12,463 volunteers aged 50+ (with half aged 65+) over two flu seasons in 7 countries. Results of the Phase 3 trial continue to be expected by the end of 2020.

About BiondVax

BiondVax is a Phase 3 clinical stage biopharmaceutical company developing a universal flu vaccine. The vaccine candidate, called M-001, is designed to provide multi-strain and multi-season protection against current and future, seasonal and pandemic influenza. BiondVax's proprietary technology utilizes a unique combination of conserved and common influenza virus peptides intended to stimulate both arms of the immune system for a cross-protecting and long-lasting effect. In a total of 7 completed Phase 1/2 and Phase 2 clinical trials enrolling 818 participants, the vaccine has been shown to be safe, well-tolerated, and immunogenic. The ongoing pivotal Phase 3 clinical trial aims to assess safety and effectiveness of M-001 in reducing flu illness and severity. For more information, please visit www.biondvax.com.

https://seekingalpha.com/pr/17876781-biondvax-announces-receipt-of-4_2-million-through-exercise-of-warrants?ifp=0&utm_medium=email&utm_source=seeking_alpha&mail_subject=pre-market-summary-on-your-portfolio-dup&utm_campaign=nl-portfolio&utm_content=link-8

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist